Nurix Therapeutics, Inc. reported $37M of revenue over the trailing twelve months, −58% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $37M (to Q2 2026). Net income: −$341M, trailing twelve months to Q2 2026. Free cash flow: −$305M, trailing twelve months to Q2 2026. Operating margin: −1073%, trailing twelve months to Q2 2026.

NRIXNurix Therapeutics, Inc.

Healthcare

$22.36+165% 1Y

$22.36

$8.2452 weeks$27.79

NRIX as reported

Nurix Therapeutics, Inc. reported $37M of revenue over the trailing twelve months, −58% on the year before. 8 reported series are charted on this page, each one as filed.

$37M

Revenue, trailing twelve months · to Q2 2026 · −58% against the twelve months before

Net income: −$341M
Net income · +65% year on year · trailing twelve months to Q2 2026
Free cash flow: −$305M
Free cash flow · +35% year on year · trailing twelve months to Q2 2026
Operating margin: −1073%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NRIX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$37M	−58%	Q2 2026
Net income	−$341M	+65%	Q2 2026
EPS	−$3.46	+33%	Q2 2026
Operating margin	−1073%	n/a	Q2 2026
Net margin	−1014%	n/a	Q2 2026
ROE	−65%	n/a	Q2 2026
ROA	−49%	n/a	Q2 2026
Free cash flow	−$305M	+35%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.